Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
The use of GnRH analogs in men has been reported in association with hyperglycemia and an increased risk of developing diabetes mellitus. Carefully weigh the known benefits and risks of GnRH agonists such as goserelin when determining appropriate treatment for prostate cancer. Periodically monitor patients' blood glucose concentration and/or glycosylated hemoglobin; hyperglycemia may represent diabetes mellitus development or worsening of glycemic control in patients with the condition. Manage patients according to current clinical practice. At this time, there are no known comparable studies evaluating the risk of diabetes in women or children taking GnRH agonists for other indications.
Treatment of children and infants on insulin therapy (including regular insulin; isophane insulin, NPH) requires special care. In general, special attention must be given to caloric intake, insulin dosage adjustments, and avoidance of low blood glucose concentrations. Because children < 5 years of age may not be able to identify symptoms of hypoglycemia, several pediatric textbooks recommend less stringent goals for fasting or preprandial blood glucose concentrations (100—200 mg/dL) and HbA1C (—9). The majority of insulin preparations have been studied in pediatric patients; however, it may be difficult to achieve glycemic control in children with fixed ratios of quick-acting and intermediate-acting insulin mixtures. When using fixed ratio mixtures of insulin, both insulin types (., the quick-acting and the intermediate-acting components) are adjusted upward or downward which may affect glycemic control undesirably.